Respiratory Infections

A look at the processes and clinical practices at place to assure candidate safety during the COVID-19 vaccine race.

How can we bridge the divide between the public and public health? Raj Bhopal argues for a strong but supportive pandemic response.

David Ho, MD, likens and contrasts the pandemic to 3 other viral outbreaks and their respective responses.

The modified adenovirus-strain candidate did not reach phase 3 assessment, and was criticized by the WHO for being rushed through assessment.

The antiviral is currently emergency authorized for treatment of severe COVID-19.

A breakdown of how COVID-19 infection was not managed well in hospitals and ICUs early on.

The clearance for the phase 2 preventive trial will seek the oral antiviral's benefit in elderly care facilities.

The authorization is for an amplicon-based next-generation sequencing test from Helix.

New joint data from the American Academy of Pediatrics and Children's Hospital Association shows 3 states make up one-fourth of all pediatric cases.

The island country of 5 million declared the pandemic over in approximately 100 days. A team of clinicians explain the decision-making and rationale which drove their successes.

A Harvard professor and study author discusses new findings showing the heightened risk of healthcare worker infection.

Raj Bhopal, BSc MD, MPH, addresses the nuances of competing ethical priorities societies face amid COVID-19, alongside political battles and terms like “herd immunity.”

David Ho, MD, shares insight into the public and scientific health shortcomings which burdened the nation back in March.

Patrick Soon-Shiong and Dr. Adam Brufsky have an open minded discussion on the dangers and potential lessons of the course Swedish health officials recommended the country take over the SARS-CoV-2 pandemic.

Will screening be based on symptoms alone? How accurate and fast must tests be?

The letter was penned by IDSA President Thomas M. File, Jr., MD, MSc, FIDSA and HIVMA Chair Judith Feinberg, MD, FIDSA on behalf of their organizations.

Peter Hotez, MD, PhD, discusses the need to take a grounded approach when discussing plans for the introduction of vaccine immunity against COVID-19.

BARDA is committing over $1 billion for the agreement, which is dependent on approval or emergency use authorization by the US FDA.

Dr. Patrick Soon-Shiong, CEO of ImmunityBio, initiates a conversation on the nature of the SARS-CoV-2 cytokine storm.

Adam Brufsky, MD, explains the insights years of research into SARS-CoV-1 may hold for SARS-CoV-2.

As the debate on hydroxychloroquine rages on, the FDA and a new advocacy group have sparred about the appropriateness of physicians prescribing the drug for COVID-19.

The trial will assess a monoclonal antibody based investigational treatment that may prevent COVID-19.

The VIP antiviral therapy shows capability in reducing COVID-19 inflammatory biomarkers, as well as respiratory failure risks.

Collodial stability measures may predict whether a potential antibody-based treatment will work early on in the drug development process.